title: Experience in the use of clobazam in the treatment of Lennox-Gastaut syndrome.
abstract: Clobazam is a 1,5-benzodiazepine used successfully worldwide since the 1970s as an anxiolytic and antiepileptic drug. Since its recent Food and Drug Administration (FDA) approval in the United States in 2011 as adjunctive treatment for Lennox-Gastaut syndrome, it has continued to show sustained efficacy and a better safety and tolerability profile compared with other benzodiazepines. The two randomized, controlled studies that led to the US FDA approval, as well as the follow-up multicenter, open-label study of clobazam, showed ≥50% seizure reduction for more than 50% of Lennox-Gastaut syndrome patients, while none of the other FDA-approved treatments for LGS have demonstrated efficacy rates better than 50%. Clobazam appears to have a safe profile and sustained effectiveness over the first 3 years of use in LGS and other epilepsy syndromes with intractable seizures, which makes it a viable long-term treatment option.
authors.affiliation: Department of Neurology, University of Oklahoma, Oklahoma City, OK, USA.
authors.forename: Gabriela
authors.initials: G
authors.lastname: Purcarin
authors.affiliation: Associate Professor, Department of Neurology, University of Oklahoma Health Sciences Center, 711 Stanton L. Young Boulevard, Suite 215, Oklahoma City, OK 73104, USA.
authors.forename: Yu-Tze
authors.initials: YT
authors.lastname: Ng
keywords: Lennox–Gastaut syndrome; benzodiazepine; clobazam; drop seizures; open-label trial; pediatric epilepsy